(2026). Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy. Forum of Clinical Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy."
Forum of Clinical Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy."
Forum of Clinical Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.